2,6-diaminobenzonitrile | 49635-80-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,6-diaminobenzonitrile
• CAS: 49635-80-5
• 化学式: C₇H₇N₃
• mdl: MFCD19203620
• 分子量: 133.153
• InChiKey: BLIPJNHFQUBALY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  75.8
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2,6-diaminobenzonitrile 在 镍 chromium(VI) oxide 、 乙醇 、 dimethyl sulfide borane 、 水 、 溶剂黄146 、 过碘酸 、 三乙胺 、 肼 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 64.0h， 生成 3-(5-ethanesulfonyl-4H-quinazolin-3-yl)-pyrrolidine-2,5-dione
  参考文献：
  名称：

  Pyrrolidine(thi)ones Substituted by Heterocyclic Substituents in The 3-Position

  摘要：

  吡咯烷(硫)酮化合物在3位被杂环取代基取代，它们的制备和在制药组合物中的用途，特别是作为免疫调节剂用于治疗和/或抑制炎症性和自身免疫疾病以及血液肿瘤性疾病。

  公开号：

  US20080293749A1
• 作为产物：
  描述：

  2,6-二硝基氯苯 在 盐酸 、 tin(ll) chloride 作用下， 生成 2,6-diaminobenzonitrile
  参考文献：
  名称：

  喹啉衍生物作为抗过敏剂。2.稠环喹啉酸。

  摘要：

  合成了一系列包含两个或多个与中心芳香核融合的4-氧代-1,4-二氢吡啶-2-羧酸单元的化合物，并在大鼠被动皮肤过敏反应（PCA）分析中测试了其潜在的抗过敏活性。该系列的大多数化合物在PCA分析中显示出显着的活性。这些化合物中的三种。11d，13f和21的活性是标准药物cromolyn钠的250倍以上。讨论了合成和生物活性。

  DOI：

  10.1021/jm00220a022

文献信息

• Novel antiallergic and antiinflammatory agents. Part II: Synthesis and pharmacology of TYB-2285 and its related compounds
  作者：Masakazu Ban、Hiroaki Taguchi、Takeo Katsushima、Mitsuru Takahashi、Kiyotaka Shinoda、Akihiko Watanabe、Takanari Tominaga

  DOI：10.1016/s0968-0896(98)00066-2

  日期：1998.7

  chloride derivatives in pyridine. Hydrolysis of acetyl compounds gave hydroxy derivatives, from which other acyl derivatives could be synthesized. These compounds were tested in the rat PCA (passive cutaneous anaphylaxis) assay by oral administration. Benzonitrile derivatives (4c, 5c, 6c, 4h, 5h) exhibited notable inhibition in this assay. Compounds 5c and 6c also showed remarkable inhibition of eosinophil

  通过在吡啶中用乙醇酰氯衍生物处理相应的间二氨基苯衍生物，合成了一系列间二（糖基氨基）苯衍生物。乙酰基化合物的水解产生羟基衍生物，从中可以合成其他酰基衍生物。这些化合物在口服PCA（被动性皮肤过敏反应）试验中进行了测试。苯甲腈衍生物（4c，5c，6c，4h，5h）在该试验中表现出显着的抑制作用。化合物5c和6c在10（-8）-10（-5）M的范围内也显示出嗜酸性粒细胞对TNF-（肿瘤坏死因子）α处理的HUVEC（人脐静脉内皮细胞）粘附的显着抑制。化合物5c是目前正在日本进行TYB-2285（图1）研究，用于II期临床研究中的哮喘和特应性皮炎。
• [EN] NEW BRAF INHIBITORS AS PARADOX BREAKERS<br/>[FR] NOUVEAUX INHIBITEURS DE BRAF EN TANT QUE "PARADOX BREAKERS"
  申请人：HOFFMANN LA ROCHE

  公开号：WO2021116050A1

  公开（公告）日：2021-06-17

  The invention provides a novel compound having the general formula (I) (I) wherein R1-R3 and X are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.

  该发明提供了一种具有通式(I)的新化合物(I)，其中R1-R3和X如描述和索赔中所定义。通式(I)的化合物可用作药物。
• Derivatives of 4,6 dioxopyrido[3,2-g]quinoline 2,8 dicarboxylic acid
  申请人：The Upjohn Company

  公开号：US03959289A1

  公开（公告）日：1976-05-25

  Novel chemical compounds of the formula: ##SPC1## Wherein R is selected from the group consisting of hydrogen, alkyl from one to three carbon atoms, inclusive, phenyl, alkali metal, or an amine cation; X and Y can be the same or different and are selected from the group consisting of hydrogen, alkyl of from one to six carbon atoms, inclusive, cycloalkyl of 5 or 6 carbon atoms, inclusive, phenyl, hydroxyl, alkoxy having from one to three carbon atoms, inclusive, halogen, trifluoromethyl, cyano, carboxyamide and O C-OQ, ##EQU1## where Q is selected from the group consisting of hydrogen, alkyl from one to three carbon atoms, inclusive, alkali metal, and an amine cation, with the proviso that where R is hydrogen, alkali metal or an amine cation, then Q is the same as R, and where R is phenyl or alkyl from one to three carbon atoms, then Q is phenyl or alkyl from one to three carbon atoms; and Z is selected from the group consisting of hydrogen, alkyl from one to three carbon atoms, inclusive, and phenyl. The compounds are formulated with pharmaceutical carriers for oral or parenteral administration, with insufflation being the preferred method. The compositions are useful in the prophylactic treatment of sensitized humans and mammals for allergy and all anaphylactic reactions of a reagin or non-reagin mediated nature.

  新化合物的化学式为：##SPC1## 其中R从氢、一至三个碳原子的烷基、苯基、碱金属或胺阳离子中选择；X和Y可以相同也可以不同，选择自氢、一至六个碳原子的烷基、五或六个碳原子的环烷基、苯基、羟基、一至三个碳原子的烷氧基、卤素、三氟甲基、氰基、羧酰胺和O C-OQ的群中，##EQU1## 其中Q从氢、一至三个碳原子的烷基、碱金属和胺阳离子中选择，但R为氢、碱金属或胺阳离子时，Q与R相同，而R为苯基或一至三个碳原子的烷基时，Q为苯基或一至三个碳原子的烷基；Z从氢、一至三个碳原子的烷基和苯基中选择。这些化合物与药用载体配方，用于口服或静脉注射，吸入为首选方法。这些组合物在预防治疗对过敏或非过敏性的变应原或非变应原介导的变应反应敏感的人类和哺乳动物中很有用。
• Novel substituted acetamide compounds and use as anti-allergic agents
  申请人：Toyo Boseki Kabushiki Kaisha

  公开号：US05041462A1

  公开（公告）日：1991-08-20

  Novel substituted acetamide compounds of the formula ##STR1## wherein R.sup.1 is hydrogen atom, a lower alkyl group, a lower acyl group, or an aryl group; R.sup.2 is cyano group or aminocarbonyl group; R.sup.3 is a halogen atom, nitro group, a lower alkoxy group, a group of the formula: --NR.sup.4 R.sup.5 (wherein R.sup.4 is hydrogen atom, a lower alkyl group or a group of the formula: --COCH.sub.2 OR.sup.1 ; R.sup.5 is hydrogen atom or a lower alkyl group), or a cyclic amino group of the formula: ##STR2## (wherein R.sup.6 and R.sup.7 are each an alkylene group having 1 to 3 carbon atoms, and X is oxygen atom or methylene), or a pharmaceutically acceptable acid addition salt thereof, which have excellent anti-allergic activity and are useful for the prophylaxis and treatment of various allergic diseases, and a pharmaceutical composition containing the amide compound as set forth above as an active ingredient.

  该专利涉及一种替代乙酰胺化合物，其化学式为 ##STR1## 其中 R.sup.1 是氢原子，低碳基，低酰基或芳基；R.sup.2 是氰基或氨基甲酰基；R.sup.3 是卤素原子，硝基，低烷氧基，公式：--NR.sup.4 R.sup.5（其中R.sup.4是氢原子，低碳基或公式：--COCH.sub.2 OR.sup.1；R.sup.5是氢原子或低碳基），或公式：##STR2##（其中R.sup.6和R.sup.7均为具有1至3个碳原子的烷基，X为氧原子或亚甲基），或其药学上可接受的酸加成盐。该化合物具有出色的抗过敏活性，可用于预防和治疗各种过敏性疾病，并且一种含有上述酰胺化合物作为活性成分的制药组合物。
• DI-Tham salt of 10-cl,1,4,6,9 tetrahydro-5-methyl 4,6
  申请人：The Upjohn Company

  公开号：US04126617A1

  公开（公告）日：1978-11-21

  Novel chemical compounds of the formula: ##STR1## wherein R is selected from the group consisting of hydrogen, alkyl from one to three carbon atoms, inclusive, phenyl, alkali metal, or an amine cation; X and Y can be the same or different and are selected from the group consisting of hydrogen, alkyl or from one to six carbon atoms, inclusive, cycloalkyl of 5 or 6 carbon atoms, inclusive, phenyl, hydroxyl, alkoxy having from one to three carbon atoms, inclusive, halogen, trifluoromethyl, cyano, carboxyamide and ##STR2## where Q is selected from the group consisting of hydrogen, alkyl from one to three carbon atoms, inclusive, alkali metal, and an amine cation, with the proviso that where R is hydrogen, alkali metal or an amine cation, then Q is the same as R, and where R is phenyl or alkyl from one to three carbon atoms, then Q is phenyl or alkyl from one to three carbon atoms; and Z is selected from the group consisting of hydrogen, alkyl from one to three carbon atoms, inclusive, and phenyl. The compounds are formulated with pharmaceutical carriers for oral or parenteral administration, with insufflation being the preferred method. The compositions are useful in the prophylactic treatment of sensitized humans and mammals for allergy and all anaphylactic reactions of a reagin or non-reagin mediated nature.

  化学物质的新型化合物的公式为：##STR1## 其中R从羟基，一到三个碳原子的烷基，苯基，碱金属或胺阳离子的组中选择；X和Y可以相同或不同，从氢，一到六个碳原子的烷基，五或六个碳原子的环烷基，苯基，羟基，一到三个碳原子的烷氧基，卤素，三氟甲基，氰基，羧酰胺和##STR2##中选择，其中Q从氢，一到三个碳原子的烷基，碱金属和胺阳离子的组中选择，但如果R为氢，碱金属或胺阳离子，则Q与R相同，如果R为苯基或一到三个碳原子的烷基，则Q为苯基或一到三个碳原子的烷基；Z从氢，一到三个碳原子的烷基和苯基中选择。这些化合物与药物载体配制，用于口服或肌肉注射，吸入为首选方法。该组成物在预防治疗对变应原或非变应原介导的过敏和全身性过敏反应的敏感人类和哺乳动物中有用。